Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 47

Sort by

Sort Order Select

Journal Articles

Itacitinib for Prevention of Graft-Versus-Host Disease and Cytokine Release Syndrome in Haploidentical Transplantation

Ramzi Abboud, Mark A. Schroeder, Michael P Rettig, Reyka G Jayasinghe, Feng Gao, Jeremy Eisele, Leah Gehrs, Julie K. Ritchey, Jaebok Choi, Camille N Abboud, Iskra Pusic, Meagan A Jacoby, Peter Westervelt, Matthew Christopher, Amanda F. Cashen, Armin Ghobadi, Keith Stockerl-Goldstein, Geoffrey L Uy, John F. DiPersio

Blood blood.2024026497.

https://doi.org/10.1182/blood.2024026497

Published: 2024

Includes: Supplemental data

Journal Articles

An “Off-the-Shelf” CD2 Universal CAR-T Therapy Combined with a Long-Acting IL-7 for T-Cell Malignancies

Jingyu Xiang, Jessica Devenport, Alun J Carter, Karl Staser, Michael P. Rettig, Miriam Y Kim, Julie O'Neal, Julie K. Ritchey, Feng Gao, Garrett Rettig, Rolf Turk, Alexandra Wolfarth, Byung Ha Lee, Matthew L. Cooper, John F. DiPersio

Blood (2023) 142 (Supplement 1): 764.

https://doi.org/10.1182/blood-2023-181087

Published: 2023

Journal Articles

Congenital Dyserythropoietic Anemia Type II: An Update from the Congenital Dyseryhtropoietic Anemia Registry of North America (CDAR)

Yasmin Elgammal, Mary Risinger, Ammar Husami, Joseph Walden, Sweta Gupta, Niketa C. Shah, James Boyer, Yasmina L. Abajas, Michael Winstead, David W. Miller, Viviana Vidal-Anaya, Adrianna Vlachos, Ashutosh Lal, Arthur K. Ritchey, Robert Lorsbach, Wenying Zhang, Theodosia A. Kalfa, Omar Niss

Blood (2023) 142 (Supplement 1): 1079.

https://doi.org/10.1182/blood-2023-189389

Published: 2023

Journal Articles

Novel Small Molecule VLA-4 Inhibitors Optimized for Extended Hematopoietic and Progenitor Cell Mobilization

Peter Ruminski, Michael P. Rettig, Stephanie Christ, Megh Singh, Ezhilarasi Chendamarai, Leah Gehrs, Julie K. Ritchey, John F. DiPersio

Blood (2023) 142 (Supplement 1): 6778.

https://doi.org/10.1182/blood-2023-181174

Published: 2023

Journal Articles

Targeting Normal Myelopoiesis Negatively Affects CAR T Cell Activity

Miriam Y Kim, Matthew L. Cooper, Julie K. Ritchey, Julie O'Neal, John DiPersio

Blood (2023) 142 (Supplement 1): 2077.

https://doi.org/10.1182/blood-2023-186015

Published: 2023

Journal Articles

Itacitinib for Prevention of Graft-Versus-Host Disease and Cytokine Release Syndrome with T-Cell Replete Peripheral Blood Haploidentical Transplantation

Ramzi Abboud, Mark A. Schroeder, Michael P. Rettig, Feng Gao, Julie K. Ritchey, Camille N. Abboud, Iskra Pusic, Peter Westervelt, Amanda F Cashen, Matt Christopher, Armin Ghobadi, Ramzi Abboud, Keith Stockerl-Goldstein, Geoffrey L Uy, John F. DiPersio, Leah Gehrs

Blood (2023) 142 (Supplement 1): 651.

https://doi.org/10.1182/blood-2023-180289

Published: 2023

Journal Articles

Mechanistic Studies of Cytokine Release Syndrome (CRS) with Roles of Interferon-Gamma (IFN-g) and Tumor Necrosis Factor Alpha (TNF-α) While Maintaining CAR-T Function in Vitro

Parmeshwar N Amatya, Jingyu Xiang, Julie O'Neal, Julie K. Ritchey, Alun J Carter, Matthew L. Cooper, John DiPersio

Blood (2023) 142 (Supplement 1): 2086.

https://doi.org/10.1182/blood-2023-187449

Published: 2023

Journal Articles

Targeting Distinct Epitopes of FCRL5 Using CAR-T Generated with Sequences Derived from Newly Identified FCRL5 Humanized Antibodies Resulted in Potent Anti-Myeloma Activity in Vitro and In Vivo

Julie O'Neal, Julie K. Ritchey, Susan Gladney, Gabriel J. Haas, Ramzi Abboud, Michael P. Rettig, Cedric Bruges, Linda Eissenberg, John F. DiPersio

Blood (2023) 142 (Supplement 1): 1922.

https://doi.org/10.1182/blood-2023-183025

Published: 2023

Journal Articles

Naked Antibody-Based Conditioning Targeting CD47 and CD117 Plus Janus Kinase Inhibition Enables Toxin-Free, Radiation-Free, and Chemotherapy-Free Fully Mismatched Allogeneic Hematopoietic Stem Cell Transplantation

Stephen P. Persaud, Aditya R. Yelamali, Julie K. Ritchey, John F. DiPersio

Blood (2023) 142 (Supplement 1): 3421.

https://doi.org/10.1182/blood-2023-174989

Published: 2023

Journal Articles

Flotetuzumab and other T-cell immunotherapies upregulate MHC class II expression on acute myeloid leukemia cells

Joseph C. Rimando, Ezhilarasi Chendamarai, Michael P. Rettig, Reyka Jayasinghe, Matthew J. Christopher, Julie K. Ritchey, Stephanie Christ, Miriam Y. Kim, Ezio Bonvini, John F. DiPersio

Blood (2023) 141 (14): 1718–1723.

https://doi.org/10.1182/blood.2022017795

Published: 2023

Includes: Supplemental data

Journal Articles

Optimized Small Molecule VLA-4 Inhibitors for Hematopoietic Stem and Progenitor Cell Mobilization

Peter Ruminski, Michael P. Rettig, Stephanie Christ, Megh Singh, Ezhilarasi Chendamarai, Leah Gehrs, Julie K. Ritchey, John F. DiPersio

Blood (2022) 140 (Supplement 1): 4477–4478.

https://doi.org/10.1182/blood-2022-159734

Published: 2022

Journal Articles

Re-Sensitization of Allogeneic T Cell Resistant Murine AML with Pegylated IFN-Gamma

Ezhilarasi Chendamarai, Julie K. Ritchey, Leah Gehrs, Michael P. Rettig, Sai Mukund Ramakrishnan, Christopher A Miller, George Cox, Lana Anderson, Timothy J Ley, John F. DiPersio

Blood (2022) 140 (Supplement 1): 7345–7346.

https://doi.org/10.1182/blood-2022-167415

Published: 2022

Journal Articles

The Dual PI3Kdg Inhibitor Duvelisib Potently Inhibits Cytokine Release Syndrome (CRS) While Maintaining CAR-T Function

Parmeshwar N. Amatya, Reyka G. Jayasinghe, Alun J. Carter, Matthew L. Cooper, Jonathan A. Pachter, John F. DiPersio, Julie K. Ritchey

Blood (2022) 140 (Supplement 1): 12686–12687.

https://doi.org/10.1182/blood-2022-167715

Published: 2022

Journal Articles

Poverty during Maintenance and Relapse Risk in Children with Acute Lymphoblastic Leukemia (ALL): A Report from Children's Oncology Group Study (COG-AALL03N1)

Aman Wadhwa, Yanjun Chen, Lindsey Hageman, Anna Hoppmann, Anne L Angiolillo, David Dickens, Glen Lew, Joseph P. Neglia, Yaddanapudi Ravindranath, Arthur K. Ritchey, Amanda Muench Termuhlen, Lennie Wong, Wendy Landier, Smita Bhatia

Blood (2022) 140 (Supplement 1): 2183–2184.

https://doi.org/10.1182/blood-2022-163271

Published: 2022

Journal Articles

Modeling Flotetuzumab-Associated CRS in AML Using in Vitro and in Vivo Preclinical Models

Dilan Anil Patel, Ezhilarasi Chendamarai, Julie K. Ritchey, Michael P. Rettig, Leah Gehrs, Paul Moore, Ralph F. Alderson, Ezio Bonvini, Matthew Christopher, John F. DiPersio

Blood (2022) 140 (Supplement 1): 8795–8796.

https://doi.org/10.1182/blood-2022-156943

Published: 2022

Journal Articles

Fully Myeloablative Antibody-Drug Conjugates Condition for Hematopoietic Stem Cell Transplantation and Provide Durable Antileukemia Benefit

Stephen P. Persaud, Aditya R. Yelamali, Julie K. Ritchey, John F. DiPersio

Blood (2022) 140 (Supplement 1): 1570–1571.

https://doi.org/10.1182/blood-2022-157726

Published: 2022

Journal Articles

Final Results of a Phase 1 Study of AntiCD19 CAR-T Cells with TNFRSF19 Transmembrane Domain

Blood (2021) 138 (Supplement 1): 3833.

https://doi.org/10.1182/blood-2021-151155

Published: 2021

Journal Articles

Does Body Mass Index (BMI) during Maintenance Influence Relapse Risk in Children with Acute Lymphoblastic Leukemia (ALL)? Results from COG-AALL03N1

Blood (2021) 138 (Supplement 1): 213.

https://doi.org/10.1182/blood-2021-148121

Published: 2021

Journal Articles

Normal Myeloid Cells Are Required for Sustained CAR T Cell Activity Against Myeloid Tumor in a Humanized Mouse Model

Miriam Y Kim, Matthew L Cooper, Julie K Ritchey, Julia Hollaway, John F. DiPersio

Blood (2021) 138 (Supplement 1): 734.

https://doi.org/10.1182/blood-2021-150935

Published: 2021

Journal Articles

Flotetuzumab and Other Cellular Immunotherapies Upregulate MHC Class II Expression on Acute Myeloid Leukemia Cells in Vitro and In Vivo

Joseph Rimando, MD, Michael P. Rettig, PhD, Matt Christopher, MD PhD, Julie K Ritchey, Miriam Y Kim, MD, John Muth, MS, Jan Davidson, John F. DiPersio, MD PhD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-133891

Published: 2020

NARROW

Itacitinib for Prevention of Graft-Versus-Host Disease and Cytokine Release Syndrome in Haploidentical Transplantation

An “Off-the-Shelf” CD2 Universal CAR-T Therapy Combined with a Long-Acting IL-7 for T-Cell Malignancies

Congenital Dyserythropoietic Anemia Type II: An Update from the Congenital Dyseryhtropoietic Anemia Registry of North America (CDAR)

Novel Small Molecule VLA-4 Inhibitors Optimized for Extended Hematopoietic and Progenitor Cell Mobilization

Targeting Normal Myelopoiesis Negatively Affects CAR T Cell Activity

Itacitinib for Prevention of Graft-Versus-Host Disease and Cytokine Release Syndrome with T-Cell Replete Peripheral Blood Haploidentical Transplantation

Mechanistic Studies of Cytokine Release Syndrome (CRS) with Roles of Interferon-Gamma (IFN-g) and Tumor Necrosis Factor Alpha (TNF-α) While Maintaining CAR-T Function in Vitro

Targeting Distinct Epitopes of FCRL5 Using CAR-T Generated with Sequences Derived from Newly Identified FCRL5 Humanized Antibodies Resulted in Potent Anti-Myeloma Activity in Vitro and In Vivo

Naked Antibody-Based Conditioning Targeting CD47 and CD117 Plus Janus Kinase Inhibition Enables Toxin-Free, Radiation-Free, and Chemotherapy-Free Fully Mismatched Allogeneic Hematopoietic Stem Cell Transplantation

Flotetuzumab and other T-cell immunotherapies upregulate MHC class II expression on acute myeloid leukemia cells

Optimized Small Molecule VLA-4 Inhibitors for Hematopoietic Stem and Progenitor Cell Mobilization

Re-Sensitization of Allogeneic T Cell Resistant Murine AML with Pegylated IFN-Gamma

The Dual PI3Kdg Inhibitor Duvelisib Potently Inhibits Cytokine Release Syndrome (CRS) While Maintaining CAR-T Function

Poverty during Maintenance and Relapse Risk in Children with Acute Lymphoblastic Leukemia (ALL): A Report from Children's Oncology Group Study (COG-AALL03N1)

Modeling Flotetuzumab-Associated CRS in AML Using in Vitro and in Vivo Preclinical Models

Fully Myeloablative Antibody-Drug Conjugates Condition for Hematopoietic Stem Cell Transplantation and Provide Durable Antileukemia Benefit

Final Results of a Phase 1 Study of AntiCD19 CAR-T Cells with TNFRSF19 Transmembrane Domain

Does Body Mass Index (BMI) during Maintenance Influence Relapse Risk in Children with Acute Lymphoblastic Leukemia (ALL)? Results from COG-AALL03N1

Normal Myeloid Cells Are Required for Sustained CAR T Cell Activity Against Myeloid Tumor in a Humanized Mouse Model

Flotetuzumab and Other Cellular Immunotherapies Upregulate MHC Class II Expression on Acute Myeloid Leukemia Cells in Vitro and In Vivo

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only